| Date Filed | Type | Description |
| 12/06/2022 |
SC 13D/A
| Atlas Venture Fund X, L.P. reports a 3% stake in REPLIMUNE GROUP, INC. |
| 09/14/2022 |
SC 13D/A
| Atlas Venture Fund X, L.P. reports a 4.4% stake in REPLIMUNE GROUP, INC. |
| 05/05/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 02/11/2022 |
SC 13D
| Atlas Venture Fund X, L.P. reports a 8.1% stake in IKENA ONCOLOGY, INC. |
| 02/11/2022 |
SC 13G/A
| Atlas Venture Fund X, L.P. reports a 11.2% stake in Kymera Therapeutics, Inc. |
| 02/11/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/17/2021 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 02/16/2021 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 02/16/2021 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/16/2021 |
SC 13G
| Atlas Venture Fund X, L.P. reports a 17.9% stake in Kymera Therapeutics, Inc. |
| 02/16/2021 |
SC 13D
| Atlas Venture Fund X, L.P. reports a 8.9% stake in GEMINI THERAPEUTICS, INC. |
| 09/17/2020 |
SC 13D/A
| Atlas Venture Fund X, L.P. reports a 6.3% stake in REPLIMUNE GROUP, INC. |
| 07/14/2020 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 07/07/2020 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 06/19/2020 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 02/13/2020 |
SC 13G/A
| Atlas Venture Fund X, L.P. reports a 10.6% stake in Magenta Therapeutics, Inc. |
| 11/25/2019 |
SC 13D
| Atlas Venture Fund X, L.P. reports a 10.8% stake in REPLIMUNE GROUP, INC. |
| 07/30/2019 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 02/13/2019 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/13/2019 |
SC 13G
| Atlas Venture Fund X, L.P. reports a 14.1% stake in REPLIMUNE GROUP, INC. |
| 02/13/2019 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 03/14/2018 |
SC 13D
| Atlas Venture Fund X, L.P. reports a 7.2% stake in SPERO THERAPEUTICS, INC. |